The European Medicines Agency (EMEA) is reviewing Acomplia a month after US regulators rejected the drug on the grounds that the drug’s benefits failed to outweigh side-affects, including suicidal thoughts and depression.
The company spent more than 10 years developing the drug.
In Europe, Acomplia has been on sale since last year. It is also marketed under the brand name Zimulti. European officials are expected to allow it to stay on the market, but with stricter warnings, Reuters said.